SCHEMBL29477247

SCHEMBL29477247

CCCCO/N=C/c1c2c(O)c3c(O)c(C)c4c(c3c1O)C(=O)[C@@](C)(O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)C(=O)N2)O4

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB11 O95342 4/20 0.77
▸ MAPT P10636 3/20 0.77
▸ ABCC4 O15439 3/20 0.77
▸ ABCC2 Q92887 3/20 0.77
▸ CHRM1 P11229 3/20 0.77
▸ ALDH1A1 P00352 2/20 0.77
▸ KDM4E B2RXH2 2/20 0.77
▸ MEN1 O00255 2/20 0.77
▸ GAA P10253 2/20 0.77
▸ MAPK1 P28482 2/20 0.77
▸ KMT2A Q03164 2/20 0.77
▸ TDP1 Q9NUW8 2/20 0.77
▸ ABCC3 O15438 2/20 0.77
▸ SLCO2B1 O94956 2/20 0.77
▸ TBXA2R P21731 2/20 0.77
▸ ADRA1A P35348 2/20 0.77
▸ SLCO1A2 P46721 2/20 0.77
▸ SLCO1B3 Q9NPD5 2/20 0.77
▸ SLCO1B1 Q9Y6L6 2/20 0.77
▸ NR1I2 O75469 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29477244 0.99 ABCB11 (0.77) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30478471 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL29477253 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30248384 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30478462 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL29477254 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30478470 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30248308 0.98 ABCB11 (0.76) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL30115796 0.97 ABCB11 (0.74) ABCB11MAPTABCC4ABCC2CHRM1
SCHEMBL29751810 0.97 ABCB11 (0.74) ABCB11MAPTABCC4ABCC2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688838-A1 MODIFIED ANTIBODIES AND USES THEREOF Gat Biosciences, S.L. (ES) 2026-02-11 — — EP disclosed
US-20260001984-A1 HIGH STRAIN HARDENING POLYETHER-ESTER MATERIAL APPLICABLE TO ELASTIC FIBER SHINKONG SYNTHETIC FIBERS CORP (TW) 2026-01-01 — — US disclosed
US-20240408211-A1 COMPOSITIONS AND METHODS OF AMELIORATING AVERSIVENESS OF AVERSIVE STIMULI BY INHIBITION OF PURINERGIC RECEPTORS BRESLIN PAUL (US) 2024-12-12 — — US disclosed
WO-2024200251-A1 MODIFIED ANTIBODIES AND USES THEREOF Gat Biosciences, S.L. (ES) 2024-10-03 — — WO disclosed
CN-116515996-A Kit for screening colorectal cancer and adenoma in progressive stage 上海伯豪生物技术有限公司 2023-08-01 — — CN disclosed
WO-2023060094-A1 COMPOSITIONS AND METHODS OF AMELIORATING AVERSIVENESS OF AVERSIVE STIMULI BY INHIBITION OF PURINERGIC RECEPTORS MONELL CHEMICAL SENSES CENTER (US) 2023-04-13 — — WO disclosed
US-11600045-B2 Collaborative light show authoring for tessellated geometries CONTRAVENTUM, LLC (US) 2023-03-07 — — US disclosed
US-20220366648-A1 Collaborative Light Show Authoring for Tessellated Geometries CONTRAVENTUM, LLC (US) 2022-11-17 — — US disclosed
US-11423190-B2 Nuclear power plant data-based design basis management system and method therefor KOREA HYDRO & NUCLEAR POWER CO., LTD (KR) 2022-08-23 — — US disclosed
US-11282276-B2 Collaborative light show authoring for tessellated geometries CONTRAVENTUM, LLC (US) 2022-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408211-A1 COMPOSITIONS AND METHODS OF AMELIORATING AVERSIVENESS OF AVERSIVE STIMULI BY INHIBITION OF PURINERGIC RECEPTORS P2RX3, P2RX2, P2RX6 ABCB11 2659/4885MAPT 4437/4885ABCC4 777/4885
US-20260001984-A1 HIGH STRAIN HARDENING POLYETHER-ESTER MATERIAL APPLICABLE TO ELASTIC FIBER ZRANB2, ZKSCAN2, ZNF787 ABCB11 925/4885MAPT 2733/4885ABCC4 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback